RXI-109(RXI-109) - 药物靶点：CTGF_在研适应症：转移性乳腺癌_专利_临床

概要

基本信息

药物类型

siRNA

别名

PH-109、RXI 109

靶点

CTGF

作用机制

CTGF抑制剂(结缔组织生长因子抑制剂)、RNA干扰

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症

转移性乳腺癌

非在研适应症

年龄相关性黄斑变性脉络膜新生血管瘢痕+ [3]

原研机构

RXi Pharmaceuticals Corp. /RNAi Technology Business/

在研机构

Phio Pharmaceuticals Corp.

非在研机构

RXi Pharmaceuticals Corp. /RNAi Technology Business/

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 29518671Antisense strand

Sequence Code 29518677Sense strand

关联

6

项与 RXI-109 相关的临床试验

NCT02599064 / Unknown status临床1/2期

A Phase 1/2 Multicenter, Multidose, Dose Escalation Study to Evaluate the Safety, Tolerability and Clinical Activity of RXI-109 Administered by Intravitreal Injection to Reduce the Progression of Subretinal Fibrosis in Subjects With Advanced Neovascular Age-related Macular Degeneration

This study is designed to evaluate the safety, tolerability and clinical activity of RXI-109 administered by intravitreal injection to reduce the progression of subretinal fibrosis in subjects with advanced neovascular age-related macular degeneration (NVAMD).

开始日期2015-11-01

申办/合作机构

RXi Pharmaceuticals Corp. /RNAi Technology Business/

NCT02246465 / Unknown status临床2期

An Open-Label, Multi-Center, Prospective, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery for Hypertrophic Scars in Healthy Adults

The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic scar.

开始日期2014-07-01

申办/合作机构

RXi Pharmaceuticals Corp. /RNAi Technology Business/

NCT02079168 / Completed临床2期

A Multi-Center, Prospective, Randomized, Single-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision.

开始日期2014-03-01

申办/合作机构

RXi Pharmaceuticals Corp. /RNAi Technology Business/

100 项与 RXI-109 相关的临床结果

登录后查看更多信息

100 项与 RXI-109 相关的转化医学

登录后查看更多信息

100 项与 RXI-109 相关的专利（医药）

登录后查看更多信息

100 项与 RXI-109 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
年龄相关性黄斑变性	临床2期	美国	RXi Pharmaceuticals Corp. /RNAi Technology Business/	2015-11-01
脉络膜新生血管	临床2期	美国	RXi Pharmaceuticals Corp. /RNAi Technology Business/	2015-11-01
视网膜下纤维化	临床2期	美国	RXi Pharmaceuticals Corp. /RNAi Technology Business/	2015-11-01
瘢痕疙瘩	临床2期	美国	RXi Pharmaceuticals Corp. /RNAi Technology Business/	2014-03-01
瘢痕疙瘩	临床2期	多米尼加共和国	RXi Pharmaceuticals Corp. /RNAi Technology Business/	2014-03-01
瘢痕	临床2期	美国	RXi Pharmaceuticals Corp. /RNAi Technology Business/	2013-11-01
瘢痕	临床2期	洪都拉斯	RXi Pharmaceuticals Corp. /RNAi Technology Business/	2013-11-01
皮肤增生性瘢痕	临床2期	美国	RXi Pharmaceuticals Corp. /RNAi Technology Business/	2013-11-01
皮肤增生性瘢痕	临床2期	洪都拉斯	RXi Pharmaceuticals Corp. /RNAi Technology Business/	2013-11-01
转移性乳腺癌	临床前	美国	Phio Pharmaceuticals Corp.	2022-11-07